Today that the U.S. Food and Drug Administration has approved an updated LDL-cholesterol lowering indication for NEXLETOL and NEXLIZET to include the treatment of primary hyperlipidemia as a qualifier for existing approved populations.
Neuland is already setting up the dedicated block for the same.
https://x.com/vivekchadha1996/status/1735174387090026971?s=46
| Subscribe To Our Free Newsletter |
